A clinical study to evaluate the advanatges and safety of long term CurQfen consumption in dementia patients
- Conditions
- Health Condition 1: null- Dementia
- Registration Number
- CTRI/2018/03/012410
- Lead Sponsor
- Akay Flavours and Aromatics Private Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 48
1. Age 55-75 Years ( Both Inclusive)
2.Male and Female Subjects
3.Patients with a MMSE Score Less than 26 and More than 14 (Both are Inclusive)
4.Must have a caregiver to attend the study visit.
5.Informed consent from Subject and Legally acceptable Representative-LAR( LAR can be Spouse/Parent/Son/Daughter/Guardian/Person Having charge or any other legally acceptable Representative)
1.Severe Memory Loss
2.Stroke
3.Psychiatric illness
4.Subjects who are under the treatment with anti Inflammatory Drugs
5.Objection from family members or any other close relatives or Legally acceptable representatives
6.If the participation in the study cause any harm to possible benefits to the patients, including Insurance benefits.
7.Objection from the Physician, under whom, current treatment is going on.
8.Patients, who are in the Clinicians judgment, are like to be placed in a nursing home, within next 6 months
9.Any condition that in Opinion of the Investigator, does not justify the Subjectsâ?? participation in the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Comparative changes in the MMSE, ACE-R, QOL,Beta Amyloid scores from baseline to Day 180.Timepoint: Day 0,Day 90,Day 180
- Secondary Outcome Measures
Name Time Method Comparative changes in the anti oxidant, anti inflammatory and safety parameters from Day 0 To day 180Timepoint: Day 0. Day 90, Day 180